| 1 | SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer | 4.2 | 139 | Citations (PDF) |
| 2 | Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. | 1.9 | 18 | Citations (PDF) |
| 3 | MET Exon 14 Skipping in Non-Small Cell Lung Cancer | 2.4 | 104 | Citations (PDF) |
| 4 | JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors | 3.9 | 63 | Citations (PDF) |
| 5 | Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors Free | 4.5 | 250 | Citations (PDF) |
| 6 | EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer Free | 4.2 | 125 | Citations (PDF) |
| 7 | Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. | 2.1 | 60 | Citations (PDF) |
| 8 | CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment. | 3.4 | 6 | Citations (PDF) |
| 9 | Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma | 4.5 | 50 | Citations (PDF) |
| 10 | The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells | 1.3 | 70 | Citations (PDF) |
| 11 | Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia | 2.8 | 86 | Citations (PDF) |
| 12 | Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010 | 11.1 | 337 | Citations (PDF) |
| 13 | Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models | 4.2 | 303 | Citations (PDF) |
| 14 | Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer | 2.0 | 40 | Citations (PDF) |
| 15 | Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer | 1.2 | 31 | Citations (PDF) |
| 16 | Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients | 1.5 | 23 | Citations (PDF) |
| 17 | Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations | 6.8 | 366 | Citations (PDF) |
| 18 | Melanoma BRAF Fusions—Response | 4.5 | 3 | Citations (PDF) |
| 19 | AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer | 6.8 | 2,101 | Citations (PDF) |
| 20 | Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs | 19.5 | 1,638 | Citations (PDF) |
| 21 | MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis | 4.8 | 63 | Citations (PDF) |
| 22 | Analysis of Major Known Driver Mutations and Prognosis in Resected Adenosquamous Lung Carcinomas | 3.1 | 62 | Citations (PDF) |
| 23 | Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes Free | 6.8 | 188 | Citations (PDF) |
| 24 | A Meta-analysis of Somatic Mutations from Next Generation Sequencing of 241 Melanomas: A Road Map for the Study of Genes with Potential Clinical Relevance | 1.2 | 91 | Citations (PDF) |
| 25 | Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies | 4.5 | 66 | Citations (PDF) |
| 26 | Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. | 2.4 | 103 | Citations (PDF) |
| 27 | Patterns and processes of somatic mutations in nine major cancers | 1.3 | 60 | Citations (PDF) |
| 28 | Acquired resistance to TKIs in solid tumours: learning from lung cancer | 54.3 | 838 | Citations (PDF) |
| 29 | Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer | 25.8 | 263 | Citations (PDF) |
| 30 | FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer | 4.5 | 141 | Citations (PDF) |
| 31 | MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis | 12.1 | 2 | Citations (PDF) |
| 32 | Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas | 2.7 | 163 | Citations (PDF) |
| 33 | Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers | 4.5 | 2,415 | Citations (PDF) |
| 34 | Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning | 1.8 | 38 | Citations (PDF) |
| 35 | Characteristics of Lung Cancers Harboring NRAS Mutations | 4.5 | 146 | Citations (PDF) |
| 36 | Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers | 5.9 | 158 | Citations (PDF) |
| 37 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease | 16.5 | 456 | Citations (PDF) |
| 38 | Mechanism for activation of mutated epidermal growth factor receptors in lung cancer | 5.3 | 133 | Citations (PDF) |
| 39 | Application of next generation sequencing to human gene fusion detection: computational tools, features and perspectives. | 4.1 | 117 | Citations (PDF) |
| 40 | American Journal of Roentgenology | 2.9 | 37 | Citations (PDF) |
| 41 | Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Free | 6.8 | 602 | Citations (PDF) |
| 42 | Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance | 3.2 | 53 | Citations (PDF) |
| 43 | DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy | 4.5 | 101 | Citations (PDF) |
| 44 | Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance | 8.7 | 97 | Citations (PDF) |
| 45 | Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains | 3.1 | 91 | Citations (PDF) |
| 46 | EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib | 3.1 | 18 | Citations (PDF) |
| 47 | Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer | 3.1 | 77 | Citations (PDF) |
| 48 | Screening for germline EGFR T790M mutations through lung cancer genotyping. | 3.1 | 128 | Citations (PDF) |
| 49 | Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis | 4.5 | 172 | Citations (PDF) |
| 50 | Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia | 14.2 | 325 | Citations (PDF) |
| 51 | Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel SequencingCell, 2012, 150, 1107-1120 | 23.8 | 1,778 | Citations (PDF) |
| 52 | Translating genomic information into clinical medicine: Lung cancer as a paradigm | 3.2 | 81 | Citations (PDF) |
| 53 | HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation Free | 6.8 | 686 | Citations (PDF) |
| 54 | Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer | 14.2 | 1,340 | Citations (PDF) |
| 55 | Consensus Rules in Variant Detection from Next-Generation Sequencing Data | 1.5 | 35 | Citations (PDF) |
| 56 | Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 | 5.3 | 441 | Citations (PDF) |
| 57 | NGS catalog: A database of next generation sequencing studies in humans† | 1.0 | 36 | Citations (PDF) |
| 58 | A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer | 2.1 | 170 | Citations (PDF) |
| 59 | Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer | 3.3 | 62 | Citations (PDF) |
| 60 | Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors | 4.2 | 217 | Citations (PDF) |
| 61 | Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling | 8.7 | 499 | Citations (PDF) |
| 62 | New driver mutations in non-small-cell lung cancer | 14.6 | 1,152 | Citations (PDF) |
| 63 | Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung Cancer | 1.0 | 30 | Citations (PDF) |
| 64 | Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations | 3.1 | 131 | Citations (PDF) |
| 65 | Genetically informed lung cancer medicine† | 3.2 | 60 | Citations (PDF) |
| 66 | Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay | 4.5 | 569 | Citations (PDF) |
| 67 | New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer | 4.5 | 341 | Citations (PDF) |
| 68 | Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene | 4.5 | 70 | Citations (PDF) |
| 69 | "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. | 0.9 | 336 | Citations (PDF) |
| 70 | Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation | 4.5 | 600 | Citations (PDF) |
| 71 | 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer | 16.5 | 263 | Citations (PDF) |
| 72 | Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib | 4.5 | 117 | Citations (PDF) |
| 73 | Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib | 4.5 | 59 | Citations (PDF) |
| 74 | How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers | 16.5 | 122 | Citations (PDF) |
| 75 | Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers | 1.5 | 214 | Citations (PDF) |
| 76 | Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations | 3.1 | 78 | Citations (PDF) |
| 77 | Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer | 3.1 | 97 | Citations (PDF) |
| 78 | Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas | 3.1 | 95 | Citations (PDF) |
| 79 | High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer | 2.0 | 207 | Citations (PDF) |
| 80 | Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer | 34.1 | 1,050 | Citations (PDF) |
| 81 | Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. | 11.2 | 41 | Citations (PDF) |
| 82 | Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer | 8.7 | 802 | Citations (PDF) |
| 83 | A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development | 4.5 | 108 | Citations (PDF) |
| 84 | Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor–Mutant Lung Cancer | 4.5 | 4 | Citations (PDF) |
| 85 | Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report | 4.5 | 87 | Citations (PDF) |
| 86 | Use of Epidermal Growth Factor Receptor/Kirsten Rat Sarcoma 2 Viral Oncogene Homolog Mutation Testing to Define Clonal Relationships Among Multiple Lung AdenocarcinomasComparison With Clinical Guidelines | 0.8 | 99 | Citations (PDF) |
| 87 | American Journal of Roentgenology | 2.9 | 118 | Citations (PDF) |
| 88 | Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers | 5.4 | 13 | Citations (PDF) |
| 89 | Tumor Progression Stage and Anatomical Site Regulate Tumor-Associated Macrophage and Bone Marrow-Derived Monocyte Polarization | 2.8 | 89 | Citations (PDF) |
| 90 | Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of <i>EGFR</i> mutant lung cancer | 6.8 | 316 | Citations (PDF) |
| 91 | Integration of Molecular Profiling into the Lung Cancer Clinic | 4.5 | 84 | Citations (PDF) |
| 92 | The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers | 5.3 | 274 | Citations (PDF) |
| 93 | Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer | 5.3 | 258 | Citations (PDF) |
| 94 | Genomic and Mutational Profiling to Assess Clonal Relationships Between Multiple Non–Small Cell Lung Cancers | 4.5 | 157 | Citations (PDF) |
| 95 | Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas | 4.5 | 187 | Citations (PDF) |
| 96 | Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications | 4.5 | 158 | Citations (PDF) |
| 97 | American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. | 16.5 | 748 | Citations (PDF) |
| 98 | Comprehensive Histologic Assessment Helps to Differentiate Multiple Lung Primary Nonsmall Cell Carcinomas From Metastases | 2.3 | 274 | Citations (PDF) |
| 99 | Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies | 14.2 | 391 | Citations (PDF) |
| 100 | High Expression Levels of Total IGF-1R and Sensitivity of NSCLC Cells In Vitro to an Anti-IGF-1R Antibody (R1507) | 1.5 | 116 | Citations (PDF) |
| 101 | Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib | 1.7 | 42 | Citations (PDF) |
| 102 | Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond | 3.8 | 341 | Citations (PDF) |
| 103 | Somatic mutations affect key pathways in lung adenocarcinoma | 31.8 | 2,808 | Citations (PDF) |
| 104 | Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib | 16.5 | 288 | Citations (PDF) |
| 105 | Constitutive Activation of Raf-1 Induces Glioma Formation in Mice | 2.9 | 78 | Citations (PDF) |
| 106 | EGFR Mutations in Lung AdenocarcinomasClinical Testing Experience and Relationship to EGFR Gene Copy Number and Immunohistochemical Expression | 2.1 | 205 | Citations (PDF) |
| 107 | Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy | 16.5 | 253 | Citations (PDF) |
| 108 | Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma | 3.1 | 259 | Citations (PDF) |
| 109 | EGFR Mutant Lung Adenocarcinomas in Patients with Germline BRCA Mutations | 3.1 | 17 | Citations (PDF) |
| 110 | Molecularly Tailored Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer: A Time for Excitement and Equipoise | 3.1 | 27 | Citations (PDF) |
| 111 | MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | 5.3 | 1,618 | Citations (PDF) |
| 112 | Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors | 1.5 | 117 | Citations (PDF) |
| 113 | Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas | 4.2 | 302 | Citations (PDF) |
| 114 | Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4 | 1.5 | 78 | Citations (PDF) |
| 115 | Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer† | 2.7 | 98 | Citations (PDF) |
| 116 | Characterizing the cancer genome in lung adenocarcinoma | 31.8 | 1,058 | Citations (PDF) |
| 117 | Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas | 6.8 | 605 | Citations (PDF) |
| 118 | Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas | 16.5 | 209 | Citations (PDF) |
| 119 | BAC Consensus Conference, November 4???6, 2004: Epidemiology, Pathogenesis, and Preclinical Models | 3.1 | 3 | Citations (PDF) |
| 120 | Defining clinically relevant molecular subsets of lung cancer | 1.3 | 17 | Citations (PDF) |
| 121 | A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer† | 2.7 | 74 | Citations (PDF) |
| 122 | Molecular On/Off Switch | 16.5 | 11 | Citations (PDF) |
| 123 | Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors | 2.9 | 467 | Citations (PDF) |
| 124 | Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib | 16.5 | 181 | Citations (PDF) |
| 125 | KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib | 4.2 | 1,374 | Citations (PDF) |
| 126 | Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain | 4.2 | 3,166 | Citations (PDF) |
| 127 | Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases | 5.3 | 541 | Citations (PDF) |
| 128 | Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas | 2.1 | 228 | Citations (PDF) |
| 129 | Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions | 16.5 | 593 | Citations (PDF) |
| 130 | Oncogenes Come of Age | 1.6 | 30 | Citations (PDF) |
| 131 | EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib | 5.3 | 4,262 | Citations (PDF) |
| 132 | Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt? | 3.3 | 36 | Citations (PDF) |
| 133 | ‘Targeting’ the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC) | 10.8 | 68 | Citations (PDF) |
| 134 | Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer | 16.5 | 733 | Citations (PDF) |
| 135 | A protein knockdown strategy to study the function of β-catenin in tumorigenesis | 4.1 | 77 | Citations (PDF) |
| 136 | P-640 Serum levels of surfactant protein D are increased in mice with lung tumors | 1.9 | 0 | Citations (PDF) |
| 137 | Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance | 5.3 | 56 | Citations (PDF) |
| 138 | Numerous eruptive lesions of panniculitis associated with group A streptococcus bacteremia in an immunocompetent child. | 3.8 | 18 | Citations (PDF) |
| 139 | Discovery and development of a bispecific antibody for the treatment of hemophilia. | 5.3 | 0 | Citations (PDF) |
